FDA delays verdict on Beren’s rare disease drug by three months

BioSpace

Beren Therapeutics is seeking approval in Neimann-Pick disease type C, an application the FDA was set to decide on by August 17.

pharminent May 29, 2026 (Last updated: May 30, 2026)

BioSpace

Beren Therapeutics is seeking approval in Neimann-Pick disease type C, an application the FDA was set to decide on by August 17.

Related Stories